SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SPCX, ASTS, RKLB Slide Overnight: Amazon Reaffirms 2026 Satellite Service Debut — Retail Weighs Competitive Threat 

Equity

Amazon’s Globalstar deal and upcoming direct-to-device network increase potential competition with ASTS.

Amazon Could Buy Viasat As AST SpaceMobile Tries Rival Bid, Satellite Consultant Says: Musk-Bezos ‘Cage Fight’ Looms

Analyst Tim Farrar said SpaceX could announce an acquisition of EchoStar’s remaining business as soon as next week.

Jeff Bezos Just Got a New Boost in His Rivalry With Elon Musk  Amazon Wins FCC Approval for $11.5 Billion Globalstar Deal to Expand Satellite Connectivity

FCC approves Amazon's Globalstar acquisition, boosting its satellite network and direct-to-device ambitions as it challenges Starlink.read more...

ASTS Stock Slips Overnight As FCC Clears Amazon’s $11.5B Globalstar Deal — Touts ‘Even More Competition’

The FCC’s review cited arguments that the deal could boost competition against AST SpaceMobile and SpaceX.

Can ASTS Turn Brazil's Spectrum Approval Into a Growth Opportunity?

ASTS secures Brazilian spectrum access to bring satellite-based calls, Internet and video to regular smartphones, targeting areas without mobile coverage.

Can AST SpaceMobile's Expanding MNO Base Boost Its Revenue Prospects?

ASTS' MNO base now spans 60+ operators and 3 billion subscribers, but satellite deployment and approvals remain key hurdles.

ASTS Stock Declines 24.4% in Six Months: Time to be Cautious?

AST SpaceMobile's 24.4% six-month slide reflects deployment, regulatory and capital risks despite strong liquidity, partnerships and broadband progress.

 Why Did Rocket Lab Hike Its Iridium Bid By 30%? Analyst Says ASTS May Have Been Mystery Rival

Farrar said AST may need telecom backing for a major spectrum deal and faces heavy competition from SpaceX.

RKLB Stock Rises Overnight: Rocket Lab’s First 8 Satellites From $143M Globalstar Deal Reach Orbit 

The satellites will support Globalstar’s direct-to-device communications and IoT services.

MDA SPACE SATELLITES FOR GLOBALSTAR SUCCESSFULLY LAUNCHED

MDA SPACE SATELLITES FOR GLOBALSTAR SUCCESSFULLY LAUNCHED MDA SPACE SATELLITES FOR GLOBALSTAR SUCCESSFULLY LAUNCHED PR Newswire TORONTO, Aug. 16, 2026 First set of eight satellites for Globalstar2-R mission deployed to low Earth orbit on a SpaceX Falcon9 rocket, marking the beginning of the...

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>Amazon kept Leo’s 2026 debut on track, with cost capitalization expected in Q1 2027.</li><li>Leo has launched nearly 400 satellites; Starlink operates over 11,000 and serves 13.6 million consumer subscribers.</li><li>AT&amp;T will offer Leo broadband to enterprise and public-sector customers.</li></ul>SpaceX (SPCX), AST SpaceMobile (ASTS) and Rocket Lab (RKLB) shares fell overnight heading into Friday, while Amazon’s reaffirmed plans to begin Leo satellite service this year kept competitive threats in focus among retail traders.<a href="https://stocktwits.com/symbol/ASTS">ASTS stock</a> fell 5%,&nbsp;<a href="https://stocktwits.com/symbol/RKLB">RKLB</a> slid 6% and&nbsp;<a href="https://stocktwits.com/symbol/SPCX">SPCX</a> dropped 4% in overnight trading heading into Friday. The declines followed a mixed regular session, when ASTS gained 2% and RKLB rose 1%, while SPCX closed 1% lower.<h2 class="st-heading-2">Amazon Keeps Its 2026 Satellite Debut On Schedule</h2>Amazon (<a class="mention" data-mention="$AMZN" data-symbol-id="AMZN" href="https://stocktwits.com/symbol/AMZN" target="_blank">AMZN</a>) CEO Andy Jassy kept the satellite-service timeline intact on Thursday’s earnings call. “Finally, Amazon Leo remains on track to begin initial service this year,” he said.CFO Brian Olsavsky also repeated the target, while flagging a later-than-expected shift in how Amazon accounts for Leo’s costs. “Amazon Leo's commercial service is on track to begin initial service this year, and we expect to begin capitalizing certain costs in Q1 of next year, including production and launch costs,” Olsavsky said. “This is later than I've been predicting in earlier earnings calls. As a result, we will continue to expense the majority of Leo-related costs in Q4.”The accounting change is now expected in the first quarter of 2027. The initial service target remains 2026.<h2 class="st-heading-2">Amazon Enters The Race With AT&amp;T In Its Corner</h2>Amazon is preparing to challenge SpaceX’s Starlink, but the gap in scale is wide. Leo has launched nearly 400 satellites across 14 missions ahead of its service debut this year. Meanwhile, SpaceX said it operated more than 11,000 Starlink satellites earlier this month.Starlink also has an established customer base. SpaceX reported 13.6 million consumer subscribers at the end of September, alongside hundreds of thousands of enterprise subscribers and more than 3,800 aircraft equipped with Starlink. Its services span homes, businesses, aviation and maritime connectivity.Amazon’s agreement with AT&amp;T (T), announced last month, also gives Leo a route into business and government customers. AT&amp;T will become the first major U.S. telecom provider to offer Leo connectivity to enterprise and public-sector customers, putting Amazon in competition for customers Starlink already serves. AT&amp;T plans to combine Leo’s satellite broadband with its fiber and 5G services, handling equipment, installation, billing and technical support.&nbsp;<h2 class="st-heading-2">Amazon Moves Closer To ASTS’ Market</h2>Amazon’s satellite ambitions also extend into AST SpaceMobile’s market: connecting phones directly from space.The FCC approved Amazon’s $11.5 billion acquisition of Globalstar (GSAT) this week, boosting its access to satellite infrastructure and mobile-satellite spectrum. The deal is expected to close in 2027. Amazon has separately proposed up to 5,105 direct-to-device satellites, with deployment beginning in 2028 — later than Leo’s initial broadband service this year.AST SpaceMobile is already building its BlueBird network to deliver cellular broadband directly to standard, unmodified smartphones. In August, it reported 13 spacecraft in orbit and preparations for beta services in 2026. It also reported partnerships with more than 60 mobile operators collectively serving over 3 billion subscribers, giving it potential distribution through existing carrier networks.Its partners include AT&amp;T, Verizon and Vodafone. AST SpaceMobile’s strategy combines carrier spectrum with access to mobile-satellite spectrum, allowing operators to extend coverage beyond their terrestrial networks.<h2 class="st-heading-2">Rocket Lab Eyes Business Behind Satellite Boom</h2>Rocket Lab’s exposure to the satellite race is different: it builds rockets, spacecraft and components for commercial, government and defense customers. Its competitive overlap with SpaceX is in launch services, while growing satellite constellations also create potential demand for its hardware.The company’s Electron rocket completed its 98th mission this month, deploying three satellites for signals-intelligence company HawkEye 360. It was Electron’s 19th launch of 2026 and its third dedicated mission for that customer.Rocket Lab is also developing Neutron, a reusable medium-lift rocket designed for larger missions, including constellation deployment. Its inaugural flight is now expected in 2027. Amazon has already booked Leo launches with Arianespace, Blue Origin, SpaceX and United Launch Alliance.<h2 class="st-heading-2">How Do Retail Traders Feel About ASTS, SPCX And RKLB?</h2>On Stocktwits, ASTS and SPCX shared ‘bearish’ retail sentiment, while RKLB held ‘neutral’. Message volume was ‘low’ across all three tickers.&nbsp;One user&nbsp;<a href="https://stocktwits.com/Imperial12/message/667705865">highlighted</a> Leo’s service timeline: “$AMZN says Leo ‘remains on track to begin initial service’ by year-end as Amazon prepares to enter satellite broadband market.”A separate trader&nbsp;<a href="https://stocktwits.com/Kevstah/message/667659878">took</a> a bullish view, saying that Amazon and Starlink’s aggressive expansion strengthened the case for AST SpaceMobile. Others speculated about Amazon acquiring ASTS.As for RKLB, the debate shifted to whether larger companies building their own satellite networks would squeeze smaller providers or create new launch opportunities. One user&nbsp;<a href="https://stocktwits.com/Benjp33/message/667689579">questioned</a> Rocket Lab’s prospects as Amazon and SpaceX expand: “What is $RKLB going to launch? The giants are taking up Space.”Another user&nbsp;<a href="https://stocktwits.com/Bee4ev/message/667714326">saw</a> a potential opening if SpaceX became less willing to launch missions for other space companies: “If Musk chooses to not service other space companies with launches, Rocket Lab will be glad to take that business.”So far this year, SPCX is down 11%, ASTS has fallen 41% and RKLB has lost 15%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-100-futures-dip-on-weak-intel-amazon-earnings-with-bloated-capex-worries-weighing-on-sentiment-amzn-intc-sbux-pltr-asts-in-focus/cZUXcXOR9Ri">Nasdaq 100 Futures Dip On Weak Intel, Amazon Earnings With Bloated Capex Worries Weighing On Sentiment —&nbsp; AMZN, INTC, SBUX, PLTR, ASTS In Focus&nbsp;</a>

 In this photo illustration, the Amazon Leo logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Amazon Is About To Take On Starlink — Space Stocks Are Trembling 

Amazon.com Inc

Tidal Trust II - Defiance Daily Target 2X Short ASTS ETF

AST SpaceMobile Inc

Tradr 2X Long ASTS Daily ETF

Tidal Trust II - Defiance Daily Target 2X Long ASTS ETF

Iridium Communications Inc

Tema Space Innovators ETF

Rocket Lab USA Inc

Defiance Daily Target 2X Long RKLB ETF

SpaceX

AT&T Inc

Show me the results

Space stocks, including $SPCX, $RKLB, and $ASTS, have been crushed in recent weeks. Is the selloff finally over? Cast your vote and drop your reasoning in the comments.

Have space stocks finally bottomed? 
 
Drop your reasoning in the comments.

Current Price	$82.30
Prev Close	$83.53
Open	$82.40
Dividend Yield	0.00%
50-Day Moving Average	$82.61
Beta	1.39
Avg. Volume	558,595.96
PE Ratio	-162.39

52-Week High	$84.85
52-Week Low	$46.50
Market Capitalization	$10.82B
EPS (Annual)	-$0.1519
Price to Book	36.44
Revenue Per Employee	$572,297.69

Feed

News

Sentiment

Earnings

Fundamentals

Info

GSAT Fundamentals